Anonymousabout 1 hour ago
Biogen announced topline results from its Phase 2 CELIA trial of diranersen (BIIB080), the first antisense oligonucleotide targeting tau protein in Alzheimer's disease, showing reductions in tau pathology and signals of cognitive benefit — but the trial failed its primary endpoint of demonstrating a dose-response relationship on the CDR-SB scale. The company plans to advance diranersen to Phase 3 despite the mixed data, a decision that raises questions about statistical rigor, the tau hypothesis, and Biogen's credibility after the aducanumab debacle.